Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 5/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | RXRA | P19793 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14213697 | 0.91 | PPARG (0.34) | PPARGCYP3A4RXRA | |
| SCHEMBL14213693 | 0.91 | PPARG (0.34) | PPARGCYP3A4RXRA | |
| SCHEMBL14213692 | 0.88 | PPARG (0.33) | PPARGCYP3A4RXRA | |
| SCHEMBL14213688 | 0.87 | PPARG (0.33) | PPARGCYP3A4RXRA | |
| SCHEMBL16491936 | 0.86 | PPARG (0.37) | PPARGCYP3A4RXRA | |
| SCHEMBL14213689 | 0.81 | PPARG (0.40) | PPARGCYP3A4RXRA | |
| SCHEMBL6928346 | 0.78 | PPARG (0.57) | PPARGCYP3A4RXRA | |
| SCHEMBL19217615 | 0.76 | PPARG (0.38) | PPARGCYP3A4RXRA | |
| SCHEMBL6928382 | 0.76 | PPARG (0.38) | PPARGCYP3A4RXRA | |
| SCHEMBL6928329 | 0.76 | PPARG (0.38) | PPARGCYP3A4RXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9126959-B2 | PPAR-sparing thiazolidinedione salts for the treatment of metabolic diseases | METABOLIC SOLUTIONS DEVELOPMENT COMPANY, LLC (US) | 2015-09-08 | — | — | US | disclosed |
| US-20150051406-A1 | PPAR-SPARING THIAZOLIDINEDIONE SALTS FOR THE TREATMENT OF METABOLIC DISEASES | CIRIUS THERAPEUTICS, INC. | 2015-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051406-A1 | PPAR-SPARING THIAZOLIDINEDIONE SALTS FOR THE TREATMENT OF METABOLIC DISEASES | PPARD, PPARG, PPARA | PPARG 2/4885CYP3A4 1260/4885RXRA 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.